https://www.selleckchem.com/pr....oducts/Paclitaxel(Ta
Longitudinal studies of SARS-CoV-2 vaccine-induced immune responses in cancer patients are needed to optimize clinical care. In a prospective cohort study of 366 (291 vaccinated) patients, we measured antibody levels [anti-spike (IgG-(S-RBD)) and anti-nucleocapsid immunoglobulin] at three timepoints. Antibody level trajectories and frequency of breakthrough infections were evaluated by tumor type and timing of treatment relative to vaccination. IgG-(S-RBD) at peak response (median=42 days after dose 2) was higher (p=0.002) and
Like
Comment
Share
